Ultralow-Dose Interleukin 10–Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

What is the safety and efficacy of interleukin 10–expressing CD19 chimeric antigen receptor (CAR) T cells (META 10-19) in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)? In this phase 1, nonrandomized clinical trial involving 13 patients with R/R DLBCL, ultralow-dose META 10-19 (2 × 10 to 2 × 10 CAR T cells/kg) achieved an objective response rate of 92.3% and complete remission rate of 84.6% among all patients who received a META 10-19 infusion, with cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome being predominantly grade 1 or 2. The results of this nonrandomized clinical trial suggest that ultralow-dose META 10-19 demonstrated promising antitumor activity, with manageable safety profiles in patients with R/R DLBCL.

Corresponding Author: He Huang, MD, PhD, Bone Marrow Transplantation Center, the First Affiliated Hospital of Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou 310058, China (huanghe@zju.edu.cn); and Xingbing Wang, MD, PhD, Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Rd No 17, Hefei 230001, China (wangxingbing@ustc.edu.cn).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.